University of California, Irvine

DARPA-funded microchip technology optimizes convalescent plasma therapy for COVID-19 patients

Newswise — Irvine, CA -  April 17, 2020 – A consortium of California scientists from government, academia and business today published an initial manuscript describing a novel approach to prepare convalescent plasma for COVID-19 patients in BioRxiv.

In the paper, senior author Saahir Khan, MD, PhD, from the University of California, Irvine Department of Medicine, reports the use of a new and more accurate way of testing for antibodies against SARS CoV-2 in recovered patients as a means to characterize the potential effectiveness of their convalescent plasma for donation to sick patients.  The project used a Defense Advanced Research Projects Agency (DARPA)-funded microchip technology, originally developed for the study of the contagiousness of influenza and other common cold infections, including common coronavirus infections.

“It appears that recovered patients have different antibodies that target COVID-19.  This tool to comprehensively measure these antibodies will allow physicians to choose the most effective donors for convalescent plasma therapy,” said Philip Felgner, PhD, the director of the UCI Vaccine R&D Center.

To reduce the risk of transfusion-transmitted infection, the consortium is using pathogen inactivation technology, developed by Cerus Corporation, to inactivate blood-borne infectious agents (e.g.,viruses, bacteria, and parasites) which may be present in the donated plasma. 

“The use of this novel microchip technology, combined with pathogen inactivation, provides a promising therapy to treat these very sick patients while reducing the risk of transfusion-transmitted infections,” said Laurence Corash, MD, chief scientific officer of Cerus Corporation.

The coronavirus antigen microarray can be used as a diagnostic and epidemiologic tool to more accurately estimate the disease burden of COVID-19 and to correlate antibody responses with clinical outcomes.

The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal  respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection,” said Khan, who designed the coronavirus antigen microarray.  “Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date.”

This research was conducted by The Convalescent Plasma for Emerging Pathogens Consortium (CPEP), a California-based partnership of academic research institutions, state public health laboratories, non-profit blood services, and biotechnology companies which are collaborating to develop platform technology for new therapies aimed at addressing the current coronavirus pandemic and future emerging pandemic pathogens. Organized by Cerus Corporation, the consortium is comprised of researchers from the California Department of Health, the Vitalant Research Institute, Vitalant Blood Services, the Vaccine Research and Development Laboratory at UCI, the California National Primate Research Center at UC Davis, Enable Biosciences, and Cerus Corporation.

This research was funded in part by the National Institutes of Health, Defense Advanced Research Projects Agency and the Defense Threat Reduction Agency.

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, and nearly 150 doctoral and master’s students. More than 700 residents and fellows are trained at UCI Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and master’s degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/master’s in public health, or an MD/master’s degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

 

###




Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.


Showing results

110 of 4573

close
1.04415